SEC and FDA Formalize Data Sharing to Catch Corporate Misstatements

Publicly traded pharmaceutical and medical device companies often move markets with updates on clinical trials and product approvals. Under the new memorandum of understanding signed August 31, the SEC gains the ability to cross-reference these corporate announcements against confidential FDA records. This setup is designed to flag potentially misleading claims in earnings releases or securities filings before they distort investor perception.

SEC Chairman Paul Atkins noted that FDA-related disclosures frequently carry significant weight in financial markets. To manage the flow of sensitive data, each agency has appointed specific divisions to handle requests, with the FDA’s Office of the Chief Counsel overseeing referrals regarding potential securities violations. Shared records remain protected by strict confidentiality safeguards, ensuring that nonpublic trade secrets or proprietary commercial information do not reach third parties without explicit authorization. While the agreement does not grant the regulators new statutory powers, it provides a streamlined mechanism to deploy existing authority more effectively. The pact remains in effect through August 2029, though either agency retains the right to terminate the arrangement with 30 days’ notice.